Invitation to presentation of Essity's Half-year Report 2023
STOCKHOLM, June 20, 2023 /PRNewswire/ -- Essity's Half-year Report for 2023 will be published on July 20, at approximately 07:00 CET. In conjunction with publication, a telephone and web presentation will be held at 09:00 CET where President and CEO Magnus Groth will present and answer questions.
Presentation: Date:Thursday, July 20, 2023 Time:09:00 CET Link to Web presentation: https://essity.videosync.fi/2023-07-20-q2 Telephone: UK: +44 (0) 33 0551 02 00, USA: +1 786 697 35 01, SWE: +46 (0) 8 505 204 24. Please call in well in advance of the start of the presentation. Indicate: "Essity" The presentation of the Interim Report will also be available on LinkedIn and Twitter
For further information, please contact: Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55, [email protected] Johan Karlsson, Vice President Investor Relations, +46 705 11 15 81, [email protected]
The professional membership group of the American Hospital Association focused on healthcare marketing has enlisted experts from the advertising agency universe and the provider data sector to share insights about the best methods for reaching and...
Team famous for HIV breakthroughs demonstrates both persistent COVID virus and widespread immune activation in long COVID; provides clear targets for treatment
Key points:
SARS-CoV-2 double-stranded RNA indicative of viral replication was found in...
CloudMD Software & Services Inc. (the "Company" or "CloudMD"), an innovative health services company transforming the delivery of care, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving...
Workers at Watsonville Community Hospital represented by Teamsters Local 853 have voted unanimously to ratify a collective bargaining agreement. The new three-year contract includes significant wage increases, a strong benefits package with Teamsters...
The global anti-inflammatory therapeutics market size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.3% during the forecast period. Increase in off-label use is...
Pulse Biosciences, Inc. (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, announced today the closing of its rights offering and the final results...
